This brief examines the implications of rising prescriptions for costly GLP-1 drugs for state Medicaid programs as more states consider covering the drugs for weight loss. It examines recent trends in Medicaid prescriptions and gross spending on GLP-1s, and explores the potential implications of expanding coverage obesity drugs for Medicaid programs.
Related Articles
Value-Based Care Is a Four Layer Cake — Why Do We Only Focus on The Icing?
During a recent panel discussion, three healthcare experts discussed reasons why value-based...
Value-Based Care Is a Four Layer Cake — Why Do We Only Focus on The Icing?
During a recent panel discussion, three healthcare experts discussed reasons why value-based...
State Reported Efforts to Address Health Disparities: A 50 State Review
This analysis focuses on current state efforts, many of which were implemented...
State Reported Efforts to Address Health Disparities: A 50 State Review
This analysis focuses on current state efforts, many of which were implemented...
Leave a comment